Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer

Phase 2

Conditions: HER-2 Positive Breast Cancer

Interventions: Drug: Trastuzumab
Drug: Paclitaxel
Drug: Carboplatin
Drug: Epirubicin

First Posted Date: 2011-09-05

Last Posted Date: 2012-08-23

Lead Sponsor: Zhimin Shao

Target Recruit Count: 100

Registration Number: NCT01428414

Locations: 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Paclitaxel
Biological: trastuzumab
Drug: Neratinib

First Posted Date: 2011-08-25

Last Posted Date: 2014-07-08

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 21

Registration Number: NCT01423123

Locations: 🇺🇸
West Virginia University Hospitals, Morgantown, West Virginia, United States
🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
NSABP Foundation, Inc., Pittsburgh, Pennsylvania, United States

and more 1 locations

A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer

Phase 2

Completed

Conditions: ER Positive, Her2 Negative Breast Cancer Patients
Triple Negative Breast Cancer Patients

Interventions: Drug: MM-121
Drug: Paclitaxel

First Posted Date: 2011-08-22

Last Posted Date: 2016-05-03

Lead Sponsor: Merrimack Pharmaceuticals

Target Recruit Count: 196

Registration Number: NCT01421472

Locations: 🇺🇸
Texas Oncology - Dallas, Dallas, Texas, United States
🇺🇸
Texas Oncology - Baylor Charles A Sammons Cancer Center, Dallas, Texas, United States
🇺🇸
University Of Chicago, Chicago, Illinois, United States

and more 34 locations

ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems

Phase 1

Withdrawn

Conditions: Neoplasms

First Posted Date: 2011-08-18

Last Posted Date: 2017-07-02

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT01419548

Locations: 🇺🇸
University of Pittsburgh Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer

Phase 3

Completed

Conditions: Stage IB Cervical Cancer AJCC v6 and v7
Cervical Adenosquamous Carcinoma
Stage IIIB Cervical Cancer AJCC v6 and v7
Stage IIA Cervical Cancer AJCC v7
Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Stage IVA Cervical Cancer AJCC v6 and v7
Cervical Adenocarcinoma
Stage IIB Cervical Cancer AJCC v6 and v7

Interventions: Radiation: Brachytherapy
Drug: Cisplatin
Drug: Carboplatin
Radiation: External Beam Radiation Therapy
Drug: Paclitaxel
Other: Quality-of-Life Assessment

First Posted Date: 2011-08-11

Last Posted Date: 2022-11-07

Lead Sponsor: GOG Foundation

Target Recruit Count: 926

Registration Number: NCT01414608

Locations: 🇺🇸
Grady Health System, Atlanta, Georgia, United States
🇺🇸
John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States
🇺🇸
UPMC-Shadyside Hospital, Pittsburgh, Pennsylvania, United States

and more 322 locations

Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Stage IV Lung Non-Small Cell Cancer AJCC v7

Interventions: Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Drug: Vorinostat
Other: Placebo Administration

First Posted Date: 2011-08-10

Last Posted Date: 2024-11-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 23

Registration Number: NCT01413750

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Southern Illinois University School of Medicine, Springfield, Illinois, United States
🇺🇸
Mercy Hospital Saint Louis, Saint Louis, Missouri, United States

and more 10 locations

Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Paclitaxel
Drug: Copanlisib (BAY80-6946)

First Posted Date: 2011-08-08

Last Posted Date: 2017-10-11

Lead Sponsor: Bayer

Target Recruit Count: 55

Registration Number: NCT01411410

Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Unspecified Adult Solid Tumor - Protocol Specific
Breast Cancer - Female

Interventions: Drug: Pazopanib
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2011-08-02

Last Posted Date: 2022-09-28

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 34

Registration Number: NCT01407562

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Study on Paclitaxel Plus Topotecan in Comparison With Topotecan Plus Cisplatin in Recurrent or Persistent Cervical Carcinoma

Phase 3

Conditions: Recurrent, Persistent or Metastasized Cervical Cancer

Interventions: Drug: Cisplatin/Paclitaxel
Drug: Paclitaxel

First Posted Date: 2011-07-29

Last Posted Date: 2012-04-12

Lead Sponsor: Institut fuer Frauengesundheit

Target Recruit Count: 312

Registration Number: NCT01405235

Locations: 🇩🇪
Universitätsfrauenklinik, Erlangen, Bavaria, Germany

Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Phase 1

Completed

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cavity Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel
Drug: pazopanib hydrochloride
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2011-07-26

Last Posted Date: 2023-12-11

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 88

Registration Number: NCT01402271

Locations: 🇪🇸
Hospital Clínico Universitario San Carlos, Madrid, Spain
🇳🇱
Radboud University Medical Center Nijmegen, Nijmegen, Netherlands
🇧🇪
C.H.U. Sart-Tilman, Liege, Belgium

and more 6 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy